Vaxcyte Completes Enrollment in All Three Adult VAX-31 Phase 3 Trials

What happened

Vaxcyte reported first-quarter 2026 financial results and confirmed that enrollment has been completed for OPUS-1, OPUS-2, and OPUS-3, the three Phase 3 trials evaluating VAX-31 for prevention of invasive pneumococcal disease and pneumonia in adults. This milestone removes the key enrollment risk and keeps the program on track for topline data from OPUS-1 in the fourth quarter of 2026 and from the other two studies in the first half of 2027. However, the stock remains highly dependent on the eventual immunogenicity and safety results—non-inferiority versus PCV20 and CAPVAXIVE is not yet proven—and investors must still weigh competitive pressure from Merck and Pfizer, manufacturing scale-up challenges, and potential dilution. The company continues to burn cash at a high rate, with $2.7 billion in cash providing runway into mid-2028, but equity issuance remains a risk given the capital intensity of commercial manufacturing build-out.

Implication

With enrollment done, the investment case now hinges entirely on OPUS data showing VAX-31's non-inferiority versus PCV20 and CAPVAXIVE. If successful, Vaxcyte could capture meaningful share in the ~$8B adult pneumococcal market; if not, the stock could fall toward cash value (~$20-25/sh). We recommend waiting for a lower entry price (~$40) or clearer data de-risking before initiating.

Thesis delta

The thesis shifts from enrollment execution risk to binary trial outcome risk. While enrollment completion is a necessary step, it does not change the fundamental risk/reward skew; we still see a 45% probability of base case ($60), 30% bear ($30), and 25% bull ($90), but the timeline to resolution is now shortened. The 'Wait' rating remains appropriate until either price declines to an attractive entry or Phase 3 data become available.